Detalles de la búsqueda
1.
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Circulation
; 122(6): 614-22, 2010 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20660806
2.
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Circulation
; 117(22): 2865-74, 2008 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-18506005
3.
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Circulation
; 114(23): 2490-7, 2006 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-17101847
4.
Improved surgeon performance in clinical trials: an analysis of quality assurance audits from the American College of Surgeons Oncology Group.
J Am Coll Surg
; 203(3): 269-76, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16931297
Resultados
1 -
4
de 4
1
Próxima >
>>